• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations.Roco 激酶结构为帕金森病相关富亮氨酸重复激酶 2 突变的机制提供了见解。
Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10322-7. doi: 10.1073/pnas.1203223109. Epub 2012 Jun 11.
2
The Parkinson disease gene LRRK2: evolutionary and structural insights.帕金森病基因LRRK2:进化与结构洞察
Mol Biol Evol. 2006 Dec;23(12):2423-33. doi: 10.1093/molbev/msl114. Epub 2006 Sep 11.
3
Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity.富含亮氨酸重复序列激酶2突变体I2020T和G2019S表现出激酶抑制剂敏感性改变。
Biochem Biophys Res Commun. 2009 Jun 26;384(2):255-8. doi: 10.1016/j.bbrc.2009.04.098. Epub 2009 May 3.
4
The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity.导致帕金森病的LRRK2突变I2020T与激酶活性增加有关。
Hum Mol Genet. 2006 Jan 15;15(2):223-32. doi: 10.1093/hmg/ddi439. Epub 2005 Dec 1.
5
Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation.富含亮氨酸重复序列激酶2(LRRK2)GTP酶和激酶结构域的结构生物学:对调节的启示
Front Mol Neurosci. 2014 May 5;7:32. doi: 10.3389/fnmol.2014.00032. eCollection 2014.
6
Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2).Rac1 蛋白挽救了 G2019S 亮氨酸丰富重复激酶 2(LRRK2)引起的神经突回缩。
J Biol Chem. 2011 May 6;286(18):16140-9. doi: 10.1074/jbc.M111.234005. Epub 2011 Mar 16.
7
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.富含亮氨酸重复激酶2中与帕金森病相关的突变增强激酶活性。
Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16842-7. doi: 10.1073/pnas.0507360102. Epub 2005 Nov 3.
8
Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.II 型激酶抑制剂对帕金森病相关 LRRK2 突变体 G2019S 表现出一种意想不到的抑制模式。
Biochemistry. 2013 Mar 12;52(10):1725-36. doi: 10.1021/bi3012077. Epub 2013 Mar 1.
9
Conformational heterogeneity of the Roc domains in C. tepidum Roc-COR and implications for human LRRK2 Parkinson mutations.嗜热栖热菌Roc-COR中Roc结构域的构象异质性及其对人类LRRK2帕金森突变的影响。
Biosci Rep. 2015 Aug 26;35(5):e00254. doi: 10.1042/BSR20150128.
10
Contribution of GTPase activity to LRRK2-associated Parkinson disease.GTP酶活性对LRRK2相关帕金森病的作用
Small GTPases. 2013 Jul-Sep;4(3):164-70. doi: 10.4161/sgtp.25130. Epub 2013 Jun 10.

引用本文的文献

1
Diverse Roles of the Multiple Phosphodiesterases in the Regulation of Cyclic Nucleotide Signaling in .多种磷酸二酯酶在[具体对象]中环核苷酸信号调节中的多样作用 。 (你提供的原文似乎不完整,缺少具体的研究对象等信息)
Cells. 2025 Apr 1;14(7):522. doi: 10.3390/cells14070522.
2
Leucine-rich repeat kinase 2 at a glance.富含亮氨酸重复激酶 2 速览。
J Cell Sci. 2023 Sep 1;136(17). doi: 10.1242/jcs.259724. Epub 2023 Sep 12.
3
LRRK2 Structure-Based Activation Mechanism and Pathogenesis.LRRK2 结构基础激活机制与发病机制。
Biomolecules. 2023 Mar 28;13(4):612. doi: 10.3390/biom13040612.
4
: A Model System for Neurological Disorders.神经系统疾病模型系统。
Cells. 2022 Jan 28;11(3):463. doi: 10.3390/cells11030463.
5
Markov State Models and Molecular Dynamics Simulations Provide Understanding of the Nucleotide-Dependent Dimerization-Based Activation of LRRK2 ROC Domain.马科夫状态模型和分子动力学模拟有助于理解基于核苷酸依赖性二聚化的 LRRK2 ROC 结构域的激活。
Molecules. 2021 Sep 17;26(18):5647. doi: 10.3390/molecules26185647.
6
A Conserved Role for LRRK2 and Roco Proteins in the Regulation of Mitochondrial Activity.LRRK2和Roco蛋白在调节线粒体活性中的保守作用。
Front Cell Dev Biol. 2021 Sep 8;9:734554. doi: 10.3389/fcell.2021.734554. eCollection 2021.
7
Pathways to Parkinson's disease: a spotlight on 14-3-3 proteins.帕金森病的发病途径:聚焦14-3-3蛋白
NPJ Parkinsons Dis. 2021 Sep 21;7(1):85. doi: 10.1038/s41531-021-00230-6.
8
LRRK2 Targeting Strategies as Potential Treatment of Parkinson's Disease.LRRK2 靶向策略作为帕金森病的潜在治疗方法。
Biomolecules. 2021 Jul 26;11(8):1101. doi: 10.3390/biom11081101.
9
Structural Biology of LRRK2 and its Interaction with Microtubules.LRRK2 的结构生物学及其与微管的相互作用。
Mov Disord. 2021 Nov;36(11):2494-2504. doi: 10.1002/mds.28755. Epub 2021 Aug 23.
10
From structure to ætiology: a new window on the biology of leucine-rich repeat kinase 2 and Parkinson's disease.从结构到病因学:LRRK2 与帕金森病生物学的新窗口。
Biochem J. 2021 Jul 30;478(14):2945-2951. doi: 10.1042/BCJ20210383.

本文引用的文献

1
The LRRK2-related Roco kinase Roco2 is regulated by Rab1A and controls the actin cytoskeleton.LRRK2 相关的 Roco 激酶 Roco2 受 Rab1A 调控,并控制肌动蛋白细胞骨架。
Mol Biol Cell. 2011 Jul 1;22(13):2198-211. doi: 10.1091/mbc.E10-12-0937. Epub 2011 May 5.
2
Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.帕金森病激酶 LRRK2 的选择性抑制剂的表征。
Nat Chem Biol. 2011 Apr;7(4):203-5. doi: 10.1038/nchembio.538. Epub 2011 Mar 6.
3
Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies.对序列变异进行推断以识别帕金森病的遗传风险:全基因组关联研究的荟萃分析。
Lancet. 2011 Feb 19;377(9766):641-9. doi: 10.1016/S0140-6736(10)62345-8. Epub 2011 Feb 1.
4
The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease.富含亮氨酸重复激酶 2(LRRK2)在帕金森病中的作用。
Nat Rev Neurosci. 2010 Dec;11(12):791-7. doi: 10.1038/nrn2935. Epub 2010 Nov 19.
5
Protein kinases: evolution of dynamic regulatory proteins.蛋白激酶:动态调节蛋白的进化。
Trends Biochem Sci. 2011 Feb;36(2):65-77. doi: 10.1016/j.tibs.2010.09.006. Epub 2010 Oct 23.
6
Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2.帕金森病相关富亮氨酸重复激酶 2 中磷酸化位点的再评价。
J Biol Chem. 2010 Sep 17;285(38):29569-76. doi: 10.1074/jbc.M110.127639. Epub 2010 Jul 1.
7
Parkinson's disease: insights from pathways.帕金森病:通路研究的新视角
Hum Mol Genet. 2010 Apr 15;19(R1):R21-7. doi: 10.1093/hmg/ddq167. Epub 2010 Apr 26.
8
Features and development of Coot.Coot的特点与发展
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501. doi: 10.1107/S0907444910007493. Epub 2010 Mar 24.
9
Characterization of the Roco protein family in Dictyostelium discoideum.盘基网柄菌中Roco蛋白家族的特征分析
Eukaryot Cell. 2010 May;9(5):751-61. doi: 10.1128/EC.00366-09. Epub 2010 Mar 26.
10
XDS.XDS.(这个词如果没有更多背景信息,很难准确翻译出更有意义的内容,直接保留原文是一种处理方式,或者音译为“克斯达斯”之类,但感觉都不太符合常规翻译场景,你可以补充更多关于这个词的信息以便我更准确翻译 )
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32. doi: 10.1107/S0907444909047337. Epub 2010 Jan 22.

Roco 激酶结构为帕金森病相关富亮氨酸重复激酶 2 突变的机制提供了见解。

Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations.

机构信息

Department of Cell Biochemistry, University of Groningen, 9747 AG, Groningen, The Netherlands.

出版信息

Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10322-7. doi: 10.1073/pnas.1203223109. Epub 2012 Jun 11.

DOI:10.1073/pnas.1203223109
PMID:22689969
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3387044/
Abstract

Mutations in human leucine-rich-repeat kinase 2 (LRRK2) have been found to be the most frequent cause of late-onset Parkinson disease. Here we show that Dictyostelium discoideum Roco4 is a suitable model to study the structural and biochemical characteristics of the LRRK2 kinase and can be used for optimization of current and identification of new LRRK2 inhibitors. We have solved the structure of Roco4 kinase wild-type, Parkinson disease-related mutants G1179S and L1180T (G2019S and I2020T in LRRK2) and the structure of Roco4 kinase in complex with the LRRK2 inhibitor H1152. Taken together, our data give important insight in the LRRK2 activation mechanism and, most importantly, explain the G2019S-related increase in LRRK2 kinase activity.

摘要

人类富含亮氨酸重复激酶 2(LRRK2)突变被发现是导致晚发性帕金森病的最常见原因。在这里,我们表明,粘菌 discoideum Roco4 是研究 LRRK2 激酶的结构和生化特性的合适模型,可用于优化现有抑制剂和鉴定新的 LRRK2 抑制剂。我们已经解决了 Roco4 激酶野生型、帕金森病相关突变 G1179S 和 L1180T(LRRK2 中的 G2019S 和 I2020T)以及 Roco4 激酶与 LRRK2 抑制剂 H1152 复合物的结构。总之,我们的数据为 LRRK2 激活机制提供了重要的见解,最重要的是,解释了 G2019S 相关的 LRRK2 激酶活性增加。